Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
Thanks for the suggestions! I'm not sure if I'll buy into any of these funds, but I wanted to know what else is out there besides XLY so that I can check them out.
Catch - That link is the motherload of Fido funds, thanks! I remember that we had …
I too would love to skewer the CEO of Turing...
Hillary's a politician who needed an excuse to change the media conversation about her away from her emails to another topic to improve her ratings. So she chose a sure-fire populist theme: healthca…
Interesting that no health care related logo is plastered onto Hillary's pantsuit in the facebook photo...
Being a cynic by nature, I'll agree with Scott's conclusion.
Hillary's focused on drug prices but this issue could spread to health care pricing in general, and on both sides of the aisle. The Republicans don't like Obamacare and Hillary wants to reign in drug prices. Either way, health care loses.
Like it or not drug pricing was bound to be an issue over the next year in the run-up to the election, at the likely expense of anything even remotely related to health care. Hillary waged war with the drug companies 20+ years ago and is doing so a…
I haven't backed up the truck with GILD shares, although I did purchase some more shares last Thursday. I'm overweight GILD in a diversified portfolio of funds/etf's and stocks and am providing facts to back up my thesis that GILD is currently an e…
Now GILD's price targets are predictably being raised:
S&P CAPITAL IQ REITERATES
STRONG BUY OPINION ON
SHARES OF GILEAD SCIENCES
Recent Price: $113.07
Recommendation:
FIVE STAR BUY [Highest Rating]
We raise our 12-month target $12 to $15…
My apologies for having momentarily hijacked this thread. I find this summary about GILD to be right on:
"What we're seeing come through is an under appreciation of all the hepatitis C revenues available outside the U.S.," said RBC Capital Markets…
The next 2 quarters will reveal GILD's expansion in countries outside of the USA, which is just beginning in Japan.
Mr. Market wants to see M&A activity from GILD. I prefer that GILD mgmt. do what is best for GILD. Can't argue with the number…
I'll be very interested in GILD's forward guidance as I think they'll top earnings estimates on Tuesday. GILD's Hep. C drugs are just getting started in large markets outside of the USA, like Japan for example. In my opinion, GILD can live off of …
I've been frustrated by GILD also. Yet sentiment toward GILD has changed since their most recent ER. One can look at GILD's chart since mid-April and say that the glass is half full, or the glass is half empty (which is my perspective).
While GIL…
@Scott - Nobody ever lost money by taking profits!
I agree with most everything that you've mentioned. Yet I think that the market has yet to fully price in the dominance of GILD's HCV cure as well as GILD's dominance in the global HCV market. I …
@Scott - You're the first person I've come across anywhere on the internet who thinks that GILD is overbought. I'm holding and not adding to my GILD position as it's a larger position than I want it to be, but I'm certainly not selling any GILD sha…
I added to my FSPHX holding this week. Still in GILD as I think it's undervalued, but I agree with the discussion that GILD is a frustrating stock. I've been through thick and thin with GILD. Both FSPHX and GILD are long term holdings for me.
I …
I'm an "emerging markets" traveler. I spent most of my early years in Thailand, so it's the country (outside of the USA) which I know best and is my fave country. Other countries I've visited, liked and would return to are (in no particular order)…
GILD has been the single most frustrating stock that I've been watching. Today might just be a short term bounce for GILD. Harvoni should be available in Japan in the 2nd half of this year as well as in various European countries where it's not ye…
Thanks for the years of links Ted. Glad you're set and thanks for keeping the links coming!
I might buy some GILD. GILD's blowout earnings and raised forecast could bode well for the entire biotech sector, which is in need of good news the kind …
I have neither the time nor the patience to watch (or listen to!) CNBC, but I come across CNBC video clips while researching funds/etf's/individual stocks. I have no idea who most of CNBC's guest "pros" are...
Only a handful of people working for my employer are over the age of 55. But I've learned that there is always an option!
Nobody on this board is aware of this fact, but I was born and spent my first 12 years of life living in Bangkok, Thailand as…
Being a cynic by nature, I also question the honesty of dentists. Dentists know that most people know little about teeth. I last saw a dentist in Nov. and he said that the next time I come in (May) I would need to get a crown. This advice came up…
I suggest HEDJ for large cap European equities and EUSC for small caps, both for the same reason which Catch already stated for HEDJ. Both etf's are WisdomTree etf's.
Note that EUSC has only been existence for a few weeks, so no track record. B…
It will be interesting to see how the iWatch does in China. The Chinese love status symbols and Apple is certainly looking more and more at China for growth.
People were skeptical about the ipad when it was introduced, then ipads became a hit once people learned how to use them. We'll just have to wait and see on the iwatch as the public hasn't been able to play with it yet. It will be interesting to s…
It's a logical conclusion that Spock will live on forever via the timeless originals of the 1960's Star Trek.
First Mork and now Spock, earth is in need of more of these friendly extraterrestrials...
Hi @PopTart,
I recall you use Fidelity. We have added to our FHLC holding, which is more so targeted (60%) towards pharma and biotech.
Fido composition view of this etf
Added: Euro against $, down -1.4% at noon, EST. -1.6% at 1pm
Lastly, geez…
I've joined the herd and bought some HEDJ. I've also added to my PJP position. I sold my FRESX holding about 2 weeks ago. It had a great 2014 but 2015 and beyond aren"t looking as kind to this fund as I had hoped.
Apple has always had many rumored products on the horizon. Innovation is Apple's well deserved reputation. I'm still waiting for the iTV rumor to come true. I can't see Apple getting into the car biz., too many moving parts (pun intended) as well…
The idea of an Apple car isn't new, I recall such rumors dating back to the 2012/2013 time period.
Apple's pps this year reminds me of the time after their hugely successful earnings report of Jan. 2012 which sent the stock soaring to new highs s…
Many thanks once again for the informative replies to my post! I'll watch all of the suggestions for awhile, although I have to admit that the case for HEDJ is perhaps most compelling.
Thanks to all for the help!
Thank you for the suggestions, I'll take a look at all of them. I'm not certain yet if I'll include any of these suggestions in my portfolio, but the replies are all most welcome. Thanks Ted for the illuminating link, I missed this article. Makes…
